Rani-Logo.jpg
Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update
August 06, 2024 16:05 ET | Rani Therapeutics, LLC
- Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity - - Phase 1 study for RT-114 expected to initiate in 2025 - - Completed...
Rani-Logo.jpg
Rani Therapeutics to Participate in August Investor Conferences
July 29, 2024 16:05 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
June 24, 2024 07:00 ET | Rani Therapeutics, LLC
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed to provide a differentiated oral delivery mechanism...
Rani-Logo.jpg
Rani Therapeutics to Participate in May Investor Conferences
May 14, 2024 08:00 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
May 09, 2024 08:00 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
May 06, 2024 16:05 ET | Rani Therapeutics, LLC
- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Initiation of Phase 2 clinical trial for RT-102 for the treatment of osteoporosis...
Rani-Logo.jpg
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
March 15, 2024 16:05 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...
Rani-Logo.jpg
Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study
October 19, 2023 16:05 ET | Rani Therapeutics, LLC
- RaniPill® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) - - RaniPill® HC has achieved a cumulative >90% success rate across multiple preclinical studies – ...
Rani-Logo.jpg
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
September 07, 2023 16:05 ET | Rani Therapeutics, LLC
- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate - Rani will continue preclinical...
Rani-Logo.jpg
Rani Therapeutics to Participate in September Investor Conferences
September 06, 2023 08:00 ET | Rani Therapeutics, LLC
SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...